Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101


USP44 suppresses pancreatic cancer progression and overcomes gemcitabine resistance by deubiquitinating FBP1.

Yang C, Zhu S, Yang H, Deng S, Fan P, Li M, Jin X.

Am J Cancer Res. 2019 Aug 1;9(8):1722-1733. eCollection 2019.


Fructose-1,6-bisphosphatase Inhibits ERK Activation and Bypasses Gemcitabine Resistance in Pancreatic Cancer by Blocking IQGAP1-MAPK Interaction.

Jin X, Pan Y, Wang L, Ma T, Zhang L, Tang AH, Billadeau DD, Wu H, Huang H.

Cancer Res. 2017 Aug 15;77(16):4328-4341. doi: 10.1158/0008-5472.CAN-16-3143. Epub 2017 Jul 18.


NPM1 activates metabolic changes by inhibiting FBP1 while promoting the tumorigenicity of pancreatic cancer cells.

Zhu Y, Shi M, Chen H, Gu J, Zhang J, Shen B, Deng X, Xie J, Zhan X, Peng C.

Oncotarget. 2015 Aug 28;6(25):21443-51.


FBP1 loss contributes to BET inhibitors resistance by undermining c-Myc expression in pancreatic ductal adenocarcinoma.

Wang B, Fan P, Zhao J, Wu H, Jin X, Wu H.

J Exp Clin Cancer Res. 2018 Sep 10;37(1):224. doi: 10.1186/s13046-018-0888-y.


Fructose-1,6-bisphosphatase is a novel regulator of Wnt/β-Catenin pathway in breast cancer.

Li K, Ying M, Feng D, Du J, Chen S, Dan B, Wang C, Wang Y.

Biomed Pharmacother. 2016 Dec;84:1144-1149. doi: 10.1016/j.biopha.2016.10.050. Epub 2016 Oct 22.


Decreased Expression of Fructose-1,6-bisphosphatase Associates with Glucose Metabolism and Tumor Progression in Hepatocellular Carcinoma.

Hirata H, Sugimachi K, Komatsu H, Ueda M, Masuda T, Uchi R, Sakimura S, Nambara S, Saito T, Shinden Y, Iguchi T, Eguchi H, Ito S, Terashima K, Sakamoto K, Hirakawa M, Honda H, Mimori K.

Cancer Res. 2016 Jun 1;76(11):3265-76. doi: 10.1158/0008-5472.CAN-15-2601. Epub 2016 Apr 6.


Periostin promotes the chemotherapy resistance to gemcitabine in pancreatic cancer.

Liu Y, Li F, Gao F, Xing L, Qin P, Liang X, Zhang J, Qiao X, Lin L, Zhao Q, Du L.

Tumour Biol. 2016 Nov;37(11):15283-15291. Epub 2016 Sep 30.


MicroRNA-410-3p attenuates gemcitabine resistance in pancreatic ductal adenocarcinoma by inhibiting HMGB1-mediated autophagy.

Xiong J, Wang D, Wei A, Ke N, Wang Y, Tang J, He S, Hu W, Liu X.

Oncotarget. 2017 Nov 18;8(64):107500-107512. doi: 10.18632/oncotarget.22494. eCollection 2017 Dec 8.


SNHG14 enhances gemcitabine resistance by sponging miR-101 to stimulate cell autophagy in pancreatic cancer.

Zhang X, Zhao P, Wang C, Xin B.

Biochem Biophys Res Commun. 2019 Mar 19;510(4):508-514. doi: 10.1016/j.bbrc.2019.01.109. Epub 2019 Feb 5.


HNF1A inhibition induces the resistance of pancreatic cancer cells to gemcitabine by targeting ABCB1.

Lu Y, Xu D, Peng J, Luo Z, Chen C, Chen Y, Chen H, Zheng M, Yin P, Wang Z.

EBioMedicine. 2019 Jun;44:403-418. doi: 10.1016/j.ebiom.2019.05.013. Epub 2019 May 15.


CBX3 promotes proliferation and regulates glycolysis via suppressing FBP1 in pancreatic cancer.

Chen LY, Cheng CS, Qu C, Wang P, Chen H, Meng ZQ, Chen Z.

Biochem Biophys Res Commun. 2018 Jun 7;500(3):691-697. doi: 10.1016/j.bbrc.2018.04.137. Epub 2018 Apr 22.


Novel crosstalk between KLF4 and ZEB1 regulates gemcitabine resistance in pancreatic ductal adenocarcinoma.

Wang Z, Chen Y, Lin Y, Wang X, Cui X, Zhang Z, Xian G, Qin C.

Int J Oncol. 2017 Oct;51(4):1239-1248. doi: 10.3892/ijo.2017.4099. Epub 2017 Aug 22.


Role of hepatocyte nuclear factor 4 alpha in cell proliferation and gemcitabine resistance in pancreatic adenocarcinoma.

Sun Q, Xu W, Ji S, Qin Y, Liu W, Hu Q, Zhang Z, Liu M, Yu X, Xu X.

Cancer Cell Int. 2019 Mar 4;19:49. doi: 10.1186/s12935-019-0767-4. eCollection 2019.


The long non-coding RNA HOTTIP promotes progression and gemcitabine resistance by regulating HOXA13 in pancreatic cancer.

Li Z, Zhao X, Zhou Y, Liu Y, Zhou Q, Ye H, Wang Y, Zeng J, Song Y, Gao W, Zheng S, Zhuang B, Chen H, Li W, Li H, Li H, Fu Z, Chen R.

J Transl Med. 2015 Mar 12;13:84. doi: 10.1186/s12967-015-0442-z.


CYR61/CCN1 Regulates dCK and CTGF and Causes Gemcitabine-resistant Phenotype in Pancreatic Ductal Adenocarcinoma.

Maity G, Ghosh A, Gupta V, Haque I, Sarkar S, Das A, Dhar K, Bhavanasi S, Gunewardena SS, Von Hoff DD, Mallik S, Kambhampati S, Banerjee SK, Banerjee S.

Mol Cancer Ther. 2019 Apr;18(4):788-800. doi: 10.1158/1535-7163.MCT-18-0899. Epub 2019 Feb 20.


Melatonin overcomes gemcitabine resistance in pancreatic ductal adenocarcinoma by abrogating nuclear factor-κB activation.

Ju HQ, Li H, Tian T, Lu YX, Bai L, Chen LZ, Sheng H, Mo HY, Zeng JB, Deng W, Chiao PJ, Xu RH.

J Pineal Res. 2016 Jan;60(1):27-38. doi: 10.1111/jpi.12285. Epub 2015 Oct 17.


USP44 Promotes the Tumorigenesis of Prostate Cancer Cells through EZH2 Protein Stabilization.

Park JM, Lee JE, Park CM, Kim JH.

Mol Cells. 2019 Jan 31;42(1):17-27. doi: 10.14348/molcells.2018.0329. Epub 2019 Jan 2.


Integrin β1 promotes gemcitabine resistance in pancreatic cancer through Cdc42 activation of PI3K p110β signaling.

Yang D, Tang Y, Fu H, Xu J, Hu Z, Zhang Y, Cai Q.

Biochem Biophys Res Commun. 2018 Oct 20;505(1):215-221. doi: 10.1016/j.bbrc.2018.09.061. Epub 2018 Sep 20.


Warburg effect revisited: an epigenetic link between glycolysis and gastric carcinogenesis.

Liu X, Wang X, Zhang J, Lam EK, Shin VY, Cheng AS, Yu J, Chan FK, Sung JJ, Jin HC.

Oncogene. 2010 Jan 21;29(3):442-50. doi: 10.1038/onc.2009.332. Epub 2009 Nov 2.


Gold Nanoparticles sensitize pancreatic cancer cells to gemcitabine.

Huai Y, Zhang Y, Xiong X, Das S, Bhattacharya R, Mukherjee P.

Cell Stress. 2019 Jul 31;3(8):267-279. doi: 10.15698/cst2019.08.195.

Supplemental Content

Support Center